Abstract
In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological patterns without even affecting the real tumor burden. Moreover, despite the intriguing results in terms of progression-free survival and response rate obtained with these agents, data about survival are superimposable with historical controls. Thus, there is a need for solid end points to evaluate the role of these agents in Phase II trials in the field of neuro-oncology.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.